Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.

Juvenile idiopathic arthritis (JIA), a type of arthritis commonly occurring in children, is a chronic, inflammatory condition ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.

The instinct to protect and secure a child’s future—especially when it comes to their health—is one of the deepest and most ...

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...

ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...